{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T15:35:36Z","timestamp":1793028936771,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ijcard.2026.134944","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:12:46Z","timestamp":1790723566000},"page":"134944","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Personalised antiplatelet therapy during elective percutaneous coronary intervention in patients with chronic coronary syndrome: An international journal of cardiology expert consensus statement"],"prefix":"10.1016","volume":"465","author":[{"given":"Francesco","family":"Pelliccia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"And\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piera","family":"Capranzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Gragnano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Patti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Italo","family":"Porto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Stefanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Zimarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Calabr\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2026.134944_bb0005","doi-asserted-by":"crossref","first-page":"e1371","DOI":"10.4244\/EIJ-D-21-00904","article-title":"Antiplatelet therapy after percutaneous coronary intervention","volume":"17","author":"Angiolillo","year":"2022","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ijcard.2026.134944_bb0010","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4244\/EIJ-D-20-00885","article-title":"Antithrombotic therapy after percutaneous coronary intervention of bifurcation lesions","volume":"171","author":"Zimarino","year":"2021","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ijcard.2026.134944_bb0015","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur. Heart J."},{"issue":"104","key":"10.1016\/j.ijcard.2026.134944_bb0020","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.amjcard.2009.07.002","article-title":"Effectiveness of two-year clopidogrel + aspirin in abolishing the risk of very late thrombosis after drug-eluting stent implantation (from the TYCOON [two-year ClOpidOgrel need] study)","volume":"15","author":"Tanzilli","year":"2009","journal-title":"Am. J. Cardiol."},{"issue":"45","key":"10.1016\/j.ijcard.2026.134944_bb0025","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"ESC guidelines for the management of chronic coronary syndromes","volume":"2024","author":"Vrints","year":"2024","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2026.134944_bb0030","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the Management of Patients with Chronic Coronary Disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on clinical practice guidelines","volume":"82","author":"Virani","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2026.134944_bb0035","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/14779072.2021.1920925","article-title":"Tackling the gap in platelet inhibition with oral antiplatelet agents in high-risk patients undergoing percutaneous coronary intervention","volume":"19","author":"Capranzano","year":"2021","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"10.1016\/j.ijcard.2026.134944_bb0040","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/14779072.2025.2544816","article-title":"Cangrelor in percutaneous coronary interventions: advances in evidence, clinical applications, and future directions","volume":"23","author":"De Sio","year":"2025","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"10.1016\/j.ijcard.2026.134944_bb0045","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jcin.2014.05.016","article-title":"Stent thrombosis","volume":"7","author":"Claessen","year":"2014","journal-title":"JACC Cardiovasc. Interv."},{"key":"10.1016\/j.ijcard.2026.134944_bb0050","doi-asserted-by":"crossref","first-page":"365","DOI":"10.31083\/j.rcm2412365","article-title":"Pathophysiology and treatment of the no-reflow phenomenon in ST-segment elevation myocardial infarction: focus on low-dose fibrinolysis during primary percutaneous intervention","volume":"24","author":"Pelliccia","year":"2023","journal-title":"Rev. Cardiovasc. Med."},{"key":"10.1016\/j.ijcard.2026.134944_bb0055","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.amjcard.2013.04.036","volume":"112","author":"Greco","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2026.134944_bb0060","doi-asserted-by":"crossref","first-page":"107361","DOI":"10.1016\/j.ahj.2026.107361","article-title":"Antiplatelet treatment after drug-coated balloon treatment: review of the current evidence and future perspectives","volume":"296","author":"Cortese","year":"2026","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2026.134944_bb0065","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/jamacardio.2024.4244","article-title":"Drug-coated balloons for the treatment of coronary artery disease: a review","volume":"10","author":"Camaj","year":"2025","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.ijcard.2026.134944_bb0070","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2026.134944_bb0075","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/eurheartj\/ehn169","article-title":"PRAGUE-8 trial Investigators. Clopidogrel pre-treatment in stable angina: for all patients > 6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8","volume":"29","author":"Widimsky","year":"2008","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2026.134944_bb0080","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jacc.2010.01.067","volume":"56","author":"Di Sciascio","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2026.134944_bb0085","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1001\/jama.2012.50788","article-title":"Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"308","author":"Bellemain-Appaix","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2026.134944_bb0090","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2165\/00003495-200565060-00001","article-title":"Optimal duration of antiplatelet therapy in recipients of coronary drug-eluting stents","volume":"65","author":"Zimarino","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.ijcard.2026.134944_bb0095","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11239-025-03136-9","article-title":"Timing, indications and transition patterns associated with cangrelor use in patients undergoing PCI","volume":"59","author":"Oliva","year":"2026","journal-title":"J. Thromb. Thrombolysis"},{"issue":"417","key":"10.1016\/j.ijcard.2026.134944_bb0100","doi-asserted-by":"crossref","first-page":"132568","DOI":"10.1016\/j.ijcard.2024.132568","article-title":"ICARUS score for predicting peri-procedural bleeding in patients undergoing percutaneous coronary intervention with cangrelor","volume":"15","author":"Benenati","year":"2024","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2026.134944_bb0105","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.117.031164","article-title":"International Expert Consensus on Switching Platelet P2Y 12 Receptor\u2013Inhibiting Therapies","volume":"136","author":"Angiolillo","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2026.134944_bb0110","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022125","article-title":"Cangrelor: clinical data, contemporary use, and future perspectives","volume":"10","author":"De Luca","year":"2021","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"10.1016\/j.ijcard.2026.134944_bb0115","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/0091270009344986","article-title":"Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist","volume":"50","author":"Akers","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ijcard.2026.134944_bb0120","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.120.046928","article-title":"Cangrelor, tirofiban, and chewed or standard prasugrel regimens in patients with ST-segment-elevation myocardial infarction: primary results of the FABOLUS-FASTER trial","volume":"142","author":"Gargiulo","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2026.134944_bb0125","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/17425255.2024.2418033","article-title":"Switching from cangrelor to oral P2Y12 inhibitors: a focused review on drug-drug interactions","volume":"21","author":"Occhipinti","year":"2025","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ijcard.2026.134944_bb0130","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jcin.2022.10.034","article-title":"Cangrelor in patients with coronary artery disease Pretreated with ticagrelor: the switching antiplatelet (SWAP)-5 study","volume":"16","author":"Franchi","year":"2023","journal-title":"JACC Cardiovasc. Interv."},{"key":"10.1016\/j.ijcard.2026.134944_bb0135","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.jcin.2026.04.047","article-title":"Pharmacodynamics of early vs delayed ticagrelor loading during Cangrelor infusion in ST-segment elevation myocardial infarction","volume":"19","author":"Grisafi","year":"2026","journal-title":"JACC Cardiovasc. Interv."},{"key":"10.1016\/j.ijcard.2026.134944_bb0140","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2026.134944_bb0145","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"CHAMPION PLATFORM Investigators. Intravenous platelet blockade with cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2026.134944_bb0150","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2026.134944_bb0155","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11239-012-0737-3","article-title":"Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials","volume":"34","author":"Angiolillo","year":"2012","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.ijcard.2026.134944_bb0160","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.amjcard.2018.12.039","article-title":"Meta-analysis of the role of Cangrelor for patients undergoing percutaneous coronary intervention","volume":"123","author":"Majmundar","year":"2019","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2026.134944_bb0165","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/ehjcvp\/pvaf042","article-title":"The role of cangrelor in acute and high-risk PCI settings","volume":"11","author":"Zeymer","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.ijcard.2026.134944_bb0170","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.jcin.2026.04.051","article-title":"Abbreviated DAPT regimens across the entire Spectrum of bleeding risk according to the PRECISE-HBR score","volume":"19","author":"Cao","year":"2026","journal-title":"JACC Cardiovasc. Interv."},{"key":"10.1016\/j.ijcard.2026.134944_bb0175","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.124.072009","article-title":"Derivation and validation of the PRECISE-HBR score to predict bleeding after percutaneous coronary intervention","volume":"151","author":"Gragnano","year":"2025","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ijcard.2026.134944_bb0180","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.119.008649","article-title":"Randomized comparison of intensified and standard P2Y12-receptor-inhibition before elective percutaneous coronary intervention: the SASSICAIA trial","volume":"13","author":"Mehilli","year":"2020","journal-title":"Circ. Cardiovasc. Interv."},{"key":"10.1016\/j.ijcard.2026.134944_bb0185","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/S0140-6736(20)32236-4","article-title":"ALPHEUS investigators. Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial","volume":"396","author":"Silvain","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2026.134944_bb0190","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jacc.2022.11.041","article-title":"Valgimigli M; single versus dual antiplatelet therapy (Sidney-2) collaboration. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after complex percutaneous coronary interventions","volume":"81","author":"Gragnano","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2026.134944_bb0195","first-page":"212","article-title":"Periprocedural myocardial infarction in patients undergoing complex versus noncomplex percutaneous coronary intervention","volume":"102","author":"Piccolo","year":"2023","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"10.1016\/j.ijcard.2026.134944_bb0200","first-page":"22","article-title":"Rotational coronary atherectomy with adjunctive balloon angioplasty for the treatment of ostial lesions","volume":"33","author":"Zimarino","year":"1994","journal-title":"Cathet. Cardiovasc. Diagn."},{"key":"10.1016\/j.ijcard.2026.134944_bb0205","doi-asserted-by":"crossref","first-page":"e1051","DOI":"10.4244\/EIJ-D-24-00992","article-title":"Antithrombotic therapy in complex percutaneous coronary intervention","volume":"21","author":"Castiello","year":"2025","journal-title":"EuroIntervention"},{"issue":"9","key":"10.1016\/j.ijcard.2026.134944_bb0210","doi-asserted-by":"crossref","first-page":"913588","DOI":"10.3389\/fcvm.2022.913588","article-title":"Temporal trends in complex percutaneous coronary interventions","volume":"24","author":"Kheifets Kheifets","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.ijcard.2026.134944_bb0215","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jcin.2023.12.011","article-title":"Ticagrelor vs clopidogrel for complex percutaneous coronary intervention in chronic coronary syndrome","volume":"17","author":"Lattuca","year":"2024","journal-title":"JACC Cardiovasc. Interv."},{"key":"10.1016\/j.ijcard.2026.134944_bb0220","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1093\/eurheartj\/ehy562","volume":"39","author":"Stone","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2026.134944_bb0225","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.jcin.2024.08.022","article-title":"Antithrombotic therapy in high bleeding risk, part I: percutaneous cardiac interventions","volume":"17","author":"Galli","year":"2024","journal-title":"JACC Cardiovasc. Interv."},{"key":"10.1016\/j.ijcard.2026.134944_bb0230","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1016\/j.jcin.2024.09.011","article-title":"Working Group of Thrombosis of the Italian Society of Cardiology. Antithrombotic Therapy in High Bleeding Risk, Part II: Noncardiac Percutaneous Interventions","volume":"vol. 17","author":"Galli","year":"2024","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ijcard.2026.134944_bb0235","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/BF03086246","article-title":"Cangrelor increases the magnitude of platelet inhibition and reduces interindividual variability in clopidogrel-pretreated subjects","volume":"17","author":"Bouman","year":"2009","journal-title":"Neth Heart J"},{"key":"10.1016\/j.ijcard.2026.134944_bb0240","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jcin.2009.10.024","article-title":"High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention","volume":"3","author":"Mangiacapra","year":"2010","journal-title":"JACC Cardiovasc. Interv."},{"key":"10.1016\/j.ijcard.2026.134944_bb0245","article-title":"Feasibility and safety of cangrelor in patients with suboptimal P2Y12 inhibition undergoing percutaneous coronary intervention: the Dutch Cangrelor registry","volume":"18;1(3):oeab028","author":"Selvarajah","year":"2021","journal-title":"Eur Heart J Open"},{"issue":"2023","key":"10.1016\/j.ijcard.2026.134944_bb0250","first-page":"3197512","article-title":"Real-world experience with Cangrelor as adjuvant to percutaneous coronary intervention: a single-Centre observational study","volume":"16","author":"Thim","year":"2023","journal-title":"Cardiol. Res. Pract."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527326007941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527326007941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T14:56:04Z","timestamp":1793026564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527326007941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":50,"alternative-id":["S0167527326007941"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2026.134944","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Personalised antiplatelet therapy during elective percutaneous coronary intervention in patients with chronic coronary syndrome: An international journal of cardiology expert consensus statement","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2026.134944","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"134944"}}